Show simple item record

dc.contributor.authorRomero-Ortuno, Roman
dc.date.accessioned2023-08-10T09:34:27Z
dc.date.available2023-08-10T09:34:27Z
dc.date.issued2023
dc.date.submitted2023en
dc.identifier.citationTeodoro J. Oscanoa, Xavier Vidal, Brady E. Beltran, Roman Romero-Ortuno, Comprehensive geriatric assessment and clinical outcomes of frail older adults with diffuse large B-cell lymphoma: a metanalysis, Oncology in Clinical Practice, 2023en
dc.identifier.otherY
dc.descriptionPUBLISHEDen
dc.description.abstractIntroduction. Comprehensive geriatric assessment (CGA) is used to personalize cancer treatments in frail older adults. However, its utility to guide treatments in frail older patients with diffuse large B-cell lymphoma (DLBCL) is not well known. We performed a meta-analysis of evidence published in this area. Material and methods. We searched PubMed and Google Scholar for studies published between January 2000 and January 2023 that included patients aged ≥ 65 years with a diagnosis of DLBCL who underwent CGA before treatment (CGA-modulated studies) and who did not (non-CGA-modulated studies). We evaluated clinical outcomes in frail/unfit patients in terms of complete response (CR), incidence of grade ≥ 3 toxicity, and 2-year overall survival (OS) in both types of studies. Results. Fifteen studies [8 CGA-modulated (n = 733, median age 76, 54% male, 52% frail/unfit) and 7 non-CGA-mod- ulated (n = 2447, median age 76, 52% male, 32% frail/unfit)] were included. In the CGA-modulated studies, the CR proportion of frail/unfit patients was 34% (95% CI 23–46%) vs. 28% (95% CI 19–38%) in the non-CGA-modulated studies (p = 0.436). Grade 3–4 hematological toxicity in frail/unfit patients was 26% (95% CI 5–55%) vs. 36% (95% CI 13–63%) (p = 0.583), respectively. Two-year OS of frail/unfit patients was 52% (95% CI 38–66%) vs. 27% (95% CI 19–36%) (p = 0.003), respectively. Conclusions. Although the proportion of frail/unfit patients was lower in non-CGA-modulated studies, CGA-mod- ulated studies reported higher OS. CGA could be useful to guide the treatment plan in older patients with DLBCL. Randomized clinical trials with standardized CGA instruments are necessary to confirm these findings.en
dc.language.isoenen
dc.relation.ispartofseriesOncology in Clinical Practice;
dc.rightsYen
dc.subjectOutcomesen
dc.subjectOlder adultsen
dc.subjectMetanalysisen
dc.subjectComprehensive geriatric assessmenten
dc.subjectDiffuse large B-cell lymphomaen
dc.subjectFrailtyen
dc.titleComprehensive geriatric assessment and clinical outcomes of frail older adults with diffuse large B-cell lymphoma: a metanalysisen
dc.typeJournal Articleen
dc.type.supercollectionscholarly_publicationsen
dc.type.supercollectionrefereed_publicationsen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/romeroor
dc.identifier.rssinternalid257586
dc.identifier.doihttps://doi.org/10.5603/OCP.2023.0021
dc.rights.ecaccessrightsopenAccess
dc.subject.TCDThemeAgeingen
dc.subject.TCDThemeCanceren
dc.subject.TCDTagFrailtyen
dc.identifier.rssurihttps://journals.viamedica.pl/oncology_in_clinical_practice/article/view/OCP.2023.0021?s=09
dc.identifier.orcid_id0000-0002-3882-7447
dc.subject.darat_impairmentAge-related disabilityen
dc.subject.darat_thematicHealthen
dc.subject.darat_thematicThird age/ageingen
dc.status.accessibleNen
dc.identifier.urihttp://hdl.handle.net/2262/103700


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record